SCHEMBL31435262

SCHEMBL31435262

C=Cc1cc(C(=O)Nc2cccc(C(F)(F)F)c2)ccn1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.64
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.58
TSHR P16473 1/20 0.58
KCNK3 O14649 2/20 0.56
P2RX1 P51575 1/20 0.55
LMNA P02545 1/20 0.55
KDM4E B2RXH2 1/20 0.55
RXFP1 Q9HBX9 2/20 0.55
HTT P42858 2/20 0.54
PTGS1 P23219 1/20 0.54
RAB9A P51151 1/20 0.54
KCNK9 Q9NPC2 1/20 0.53
AURKA O14965 1/20 0.53
KCNQ3 O43525 1/20 0.52
KCNQ2 O43526 1/20 0.52
KCNE1 P15382 1/20 0.52
KCNQ1 P51787 1/20 0.52
KCNQ5 Q9NR82 1/20 0.52
LCK P06239 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4600071 0.83 MAPT (0.70) MAPTKMT2AMEN1TSHRKCNK3
SCHEMBL31435249 0.81 MAPT (0.68) MAPTKMT2AMEN1TSHRKCNK3
SCHEMBL15238350 0.81 MAPT (0.68) MAPTKMT2AMEN1TSHRKCNK3
SCHEMBL31435257 0.81 MAPT (0.68) MAPTKMT2AMEN1TSHRKCNK3
SCHEMBL3486022 0.79 RXFP1 (0.79) MAPTKMT2AMEN1TSHRKCNK3
SCHEMBL4286068 0.79 MAPT (0.94) MAPTKMT2AMEN1TSHRKCNK3
SCHEMBL24141032 0.77 MAPT (0.84) MAPTKMT2AMEN1TSHRKCNK3
SCHEMBL16011453 0.76 MAPT (0.64) MAPTKMT2AMEN1KCNK3P2RX1
SCHEMBL26093101 0.76 MAPT (0.64) MAPTKMT2AMEN1KCNK3P2RX1
SCHEMBL23447711 0.76 MAPT (0.82) MAPTKMT2AMEN1TSHRKCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025090928-A9 COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES AQUINNAH PHARMACEUTICALS, INC. (US) 2026-04-30 WO disclosed
WO-2025090928-A1 COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES AQUINNAH PHARMACEUTICALS, INC. (US) 2025-05-01 WO disclosed